CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.34B, above the global median of $1.18B
- FinancialsAltman Z-Score 11.75: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.96BCNY1.34B · vs all stocks (USD)
Revenue (TTM)
469.17MCNY70.03M · vs all stocks (USD)
Profit Margin
-55.30%vs Biotechnology peers
Beta
0.3700xvs all stocks
52-Week Change
-46.11%vs all stocks
Market Capitalization
8.96BCNY1.34B · vs all stocks (USD)
Enterprise Value
6.73BCNY1.00B · vs all stocks (USD)
Price to Sales (TTM)
17.45xvs Biotechnology peers
Price to Book (MRQ)
3.19xvs Biotechnology peers
Enterprise to Revenue
14.35xvs Biotechnology peers
Enterprise to EBITDA
-27.00xvs Biotechnology peers
Gross Margin
75.92%vs Biotechnology peers
Profit Margin
-55.30%vs Biotechnology peers
Operating Margin
-47.10%vs Biotechnology peers
Return on Assets (TTM)
-6.45%vs Biotechnology peers
Return on Equity (TTM)
-11.65%vs Biotechnology peers
Revenue (TTM)
469.17MCNY70.03M · vs all stocks (USD)
Revenue per Share (TTM)
5.05CNYUpdated Sep 22, 2026Quarterly Revenue Growth
37.70%vs Biotechnology peers
Gross Profit (TTM)
287.12MCNY42.86M · vs all stocks (USD)
EBITDA (TTM)
-249.26MCNY-37.21M · vs all stocks (USD)
Net Income (TTM)
-259.44MCNY-38.73M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
37.09%vs Biotechnology peers
Operating Cash Flow (TTM)
-181.28MCNY-27.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-291.74MCNY-43.55M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
170.32MCNYFY2025 · Dec 31, 2025Revenue
404.88MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
171.78MCNYFY2025 · Dec 31, 2025Gross Profit
233.09MCNYFY2025 · Dec 31, 2025Operating Income
-249.47MCNY-37.24M · vs all stocks (USD)
Pre-tax Income
-267.28MCNYFY2025 · Dec 31, 2025Income Tax Expense
-8.64MCNYFY2025 · Dec 31, 2025Net Income
-258.63MCNYFY2025 · Dec 31, 2025EBIT
-258.48MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-90.57MCNYFY2025 · Dec 31, 2025Research & Development
162.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
130.50MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
21.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
8.80MCNYFY2025 · Dec 31, 2025EPS (Basic)
-2.50CNYFY2025 · Dec 31, 2025EPS (Diluted)
-2.50CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
86.42MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
86.42MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-258.63MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
42.59MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-186.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
-228.43MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
536.83MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-258.63MCNYFY2025 · Dec 31, 2025Other Non-cash Items
16.22MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
51.24MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.62MCNYFY2025 · Dec 31, 2025Capital Expenditures
-41.87MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.70BCNYFY2025 · Dec 31, 2025Sale of Investments
4.99BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
248.92MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
321.18MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-46.82MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-1.74MCNYFY2025 · Dec 31, 2025Other Financing Charges
-184.84MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
87.78MCNYFY2025 · Dec 31, 2025Shares Outstanding
92.75MSharesUpdated Sep 22, 2026Float Shares
60.02MSharesUpdated Sep 22, 2026% Held by Insiders
32.20%vs all stocks
% Held by Institutions
16.54%vs all stocks
Total Cash (MRQ)
1.20BCNY179.17M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.61CNYUpdated Sep 22, 2026Total Debt (MRQ)
98.45KCNY14.70K · vs all stocks (USD)
Current Ratio (MRQ)
8.13xvs Biotechnology peers
Book Value per Share (MRQ)
27.69CNYUpdated Sep 22, 2026Total Assets
3.18BCNY474.66M · vs all stocks (USD)
Total Current Assets
1.60BCNYFY2025 · Dec 31, 2025Total Liabilities
523.29MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.58BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
275.25MCNYFY2025 · Dec 31, 2025Total Current Liabilities
248.03MCNYFY2025 · Dec 31, 2025Cash
534.09MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
536.84MCNYFY2025 · Dec 31, 2025Other Short-term Investments
830.33MCNYFY2025 · Dec 31, 2025Accounts Receivable
118.03MCNYFY2025 · Dec 31, 2025Inventory
79.36MCNYFY2025 · Dec 31, 2025Accounts Payable
105.21MCNYFY2025 · Dec 31, 2025Short-term Debt
50.36MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.38MCNYFY2025 · Dec 31, 2025Long-term Debt
130.44KCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
264.05MCNYFY2025 · Dec 31, 2025Common Stock (Book)
92.71MCNYFY2025 · Dec 31, 2025Retained Earnings
2.50BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.66BCNY396.55M · vs all stocks (USD)
Treasury Stock
338.55MCNYFY2025 · Dec 31, 202552-Week Low
73.44CNYUpdated Sep 22, 202652-Week High
214.78CNYUpdated Sep 22, 202652-Week Change
-46.11%vs all stocks
Beta
0.3700xvs all stocks
50-Day MA
106.27CNYUpdated Sep 22, 2026200-Day MA
121.40CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.12MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.16MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-2.94CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.76Profit Margin: -0.55
Financial Health
Altman Z-Score 11.75: safe zoneNotable
Altman Z-Score: 11.75
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.34B, above the global median of $1.18BNotable
Market cap (USD): 1,338,158,576.373Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beijing Yjk Building Software Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDown-Close Share With Multi-Year Earnings Decrease
Bin Chuan Enterprise Co., Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
National Silicon Industry Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDown-Close Share With Multi-Year Earnings Decrease